PDCD4-IN-1
CAS No. 494763-64-3
PDCD4-IN-1( —— )
Catalog No. M36425 CAS No. 494763-64-3
PDCD4-IN-1, a PDCD4 inhibitor (Kd : 350 nM), promotes BDNF expression in hippocampal neuronal cells HT-22.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 29 | In Stock |
|
| 10MG | 46 | In Stock |
|
| 25MG | 93 | In Stock |
|
| 50MG | 147 | In Stock |
|
| 100MG | 231 | In Stock |
|
| 200MG | 337 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePDCD4-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionPDCD4-IN-1, a PDCD4 inhibitor (Kd : 350 nM), promotes BDNF expression in hippocampal neuronal cells HT-22.
-
DescriptionPDCD4-IN-1(compound 20031600) is a PDCD4 inhibitor with a Kd value of 350 nM, which can promote the expression of BDNF in hippocampal neuron cell HT-22.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number494763-64-3
-
Formula Weight326.58
-
Molecular FormulaC12H9BrClN3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (765.51 mM; Ultrasonic )
-
SMILESC(NNC1=CC(Cl)=CC=C1)(=O)C=2C=C(Br)C=NC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Application of ligand small molecule of targeting PDCD4 in preparation of antidepressant drugs. CN115385914.
molnova catalog
related products
-
Catch-Relaxing Pepti...
Catch-Relaxing Peptide (CARP)
-
Methyl retinoate
Methyl retinoate (Retinoic acid, methyl ester) induces aseptic inflammation at the site of administration in in vivo experiments, which causes an increase in the number of leukocytes in the blood and a decrease in the levels of red blood cells and Hb.Methyl retinoate promotes spontaneous leukemia.Methyl retinoate can be Used in the treatment of gastric hypertrophy and ulcers due to vitamin A deficiency.
-
DUPA
DUPA is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
Cart
sales@molnova.com